Xeris (XERS) Q2 Revenue Jumps 49%
Xeris Biopharma (NASDAQ:XERS), a specialty pharmaceutical company focused on developing and commercializing injectable therapies, reported its Q2 2025 earnings on August 7, 2025. The release revealed record revenue and a notable swing to positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) (non-GAAP). Second-quarter revenue (GAAP) was $71.5 million, surpassing consensus estimates by $7.1 million (GAAP) (up 48.8% year over year (GAAP)), while net loss per share (GAAP) improved to $(0.01), beating the analysts' estimate of $(0.028). These results were fueled largely by the continued rapid growth of Recorlev, Xeris's lead therapy for Cushing’s syndrome, with Recorlev net revenue increasing approximately 136% year-over-year. The company’s adjusted EBITDA (non-GAAP) turned positive at $12.5 million, a substantial turnaround from a negative figure in the prior year. Based on these results, Xeris raised its full-year 2025 total revenue guidance (GAAP) to $280–$290 million (up from $260–$275 million), pointing to continued commercial momentum and confidence in its pipeline and product portfolio. Overall, the company delivered on key commercial and financial targets during the quarter.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Xeris Biopharma specializes in making injectable drugs more accessible and user-friendly, largely through its proprietary formulation technologies. Its core commercial products are Recorlev (used to treat Cushing’s syndrome), Gvoke (for severe hypoglycemia), and Keveyis (used in treating primary periodic paralysis, a rare neuromuscular disorder).
Source Fool.com
